The influence of HDBA organic complex with vitamin d and calcium on quality of life in individuals at high risk of fractures undergoing medical rehabilitation

Abstract

The aim of the study is to evaluate the effect of the biologically active food supplement «Osteomed Forte» on pain intensity and quality of life in patients with high risk of fractures undergoing medical rehabilitation. Materials and methods: Included men and women 40-80 years old, with high risk of fractures. Patients who had already taken antiresorbents were identified in group №1 - they were assigned the investigated product (IP): biologically active food supplement «Osteomed Forte». Patients who had not received antiresorption therapy were divided into two equal groups by simple randomization. Group №2 was assigned to IP. There were no IPs in group №3. All the subjects were conducted: 1. Pain Assessment Score (PAS); 2. Quality of Life Assessment (QUALEFFO-41). The examination was repeated immediately after the rehabilitation course as well as after 6 and 12 months. Results: The study enrolled 120 people (group №1 n=41, group №2 n=39, group №3 n=39): 10 men, 110 women, average age 65.51±7.92 years. After a course of rehabilitation in all groups, PAS was significantly reduced (2.7, 3.0, 3.5 points, respectively, p<0.01), and the QUALEFFO-41 scores improved on all scales (p<0.05). This trend continued after 6 months. After 12 months, a significantly lower PAS was in group №1 (4.0 as compared to 6.2 and 6.4 points, p<0.05). In group №1, QUALEFFO-41 indices were significantly better than the initial ones (p<0,05) and higher than in groups №2 and 3 «Pain», «Housework», «Mobility», «General Health», «Mental Health», «General Indicator» (p<0,05). Conclusion: In patients with a high risk of fractures, the course of medical rehabilitation improved the physical and mental components of QOL and reduced the pain syndrome. In patients who took IP as a basic therapy, the achieved effect was maintained after 3, 6, 12 months. In 1 year after the rehabilitation course, the groups receiving IP and antiresorption therapy had better QOL parameters, lower PAS and better bone metabolism indices.